(Stroke. 2000;31:817.)
© 2000 American Heart Association, Inc.
Original Contributions |
Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation
A Multicenter, Prospective, Randomized Trial
From the National Cardiovascular Center, Osaka, Japan.
Correspondence to Takenori Yamaguchi, MD, Director General of the Hospital, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan. E-mail tyamaguc{at}hsp.ncvc.go.jp
Background and Purpose—The optimal intensity of warfarin therapy for secondary prevention of stroke in nonvalvular atrial fibrillation (NVAF) remains unclear. We studied the efficacy and safety of conventional- and low-intensity warfarin therapy in a prospective, randomized, multicenter trial.
Methods—The study population consisted of patients with NVAF (<80 years old) who had a stroke or transient ischemic attack. The patients were randomly allocated into a conventional-intensity group (international normalized ratio [INR] 2.2 to 3.5) and a low-intensity group (INR 1.5 to 2.1). They were carefully monitored, and the annual rate of recurrent ischemic stroke and major hemorrhagic complications were compared between the groups.
Results—We enrolled 115 patients (mean age 66.7±6.5 years) into the study. Fifty-five and 60 patients were allocated into the conventional- and low-intensity groups, respectively. The trial was stopped after a follow-up of 658±423 days, when major hemorrhagic complications occurred in 6 patients of the conventional-intensity group and the frequency (6.6% per year) was significantly higher than that in the low-intensity group (0% per year, P=0.01, Fisher’s exact test). All of the 6 patients with major bleeding were elderly (mean age 74 years), and their mean INR before the major hemorrhage was 2.8. The annual rate of ischemic stroke was low in both groups (1.1% per year in the conventional-intensity group and 1.7% per year in the low-intensity groups) and did not differ significantly.
Conclusions—For secondary prevention of stroke in persons with NVAF, especially in old patients, the low-intensity warfarin (INR 1.5 to 2.1) treatment seems to be safer than the conventional-intensity (INR 2.2 to 3.5) treatment.
Key Words: atrial fibrillation • cerebrovascular disorders • prevention • randomized controlled trials • warfarin
This article has been cited by other articles:
 |
|
 |
|
  S-Y Lee The type of the patient should be considered on discontinuation of anticoagulant and antiplatelet therapy Gut, January 1, 2009; 58(1): 153 - 154. [Full Text] [PDF]
|
|
|
|
 |
|
 L V Andersen, P Vestergaard, P Deichgraeber, J S Lindholt, L S Mortensen, and L Frost Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis Heart, December 1, 2008; 94(12): 1607 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Toyoda, M. Yasaka, K. Iwade, K. Nagata, Y. Koretsune, T. Sakamoto, S. Uchiyama, J. Gotoh, T. Nagao, M. Yamamoto, et al. Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease: A Prospective, Multicenter, Observational Study Stroke, June 1, 2008; 39(6): 1740 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Garwood and T. L Corbett Use of Anticoagulation in Elderly Patients with Atrial Fibrillation Who Are at Risk for Falls Ann. Pharmacother., April 1, 2008; 42(4): 523 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Hart, L. A. Pearce, and M. I. Aguilar Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation Ann Intern Med, June 19, 2007; 146(12): 857 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Oake, D. A. Fergusson, A. J. Forster, and C. van Walraven Frequency of adverse events in patients with poor anticoagulation: a meta-analysis Can. Med. Assoc. J., May 22, 2007; 176(11): 1589 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Monte, A. Macchia, F. Pellegrini, M. Romero, V. Lepore, A. D'Ettorre, M. Saugo, L. Tavazzi, and G. Tognoni Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation Eur. Heart J., September 2, 2006; 27(18): 2217 - 2223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Cooper, A. J. Sutton, G. Lu, and K. Khunti Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med, June 26, 2006; 166(12): 1269 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sato, K. Ishikawa, A. Kitabatake, S. Ogawa, Y. Maruyama, Y. Yokota, T. Fukuyama, Y. Doi, S. Mochizuki, T. Izumi, et al. Low-Dose Aspirin for Prevention of Stroke in Low-Risk Patients With Atrial Fibrillation: Japan Atrial Fibrillation Stroke Trial Stroke, February 1, 2006; 37(2): 447 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Hackam, A. Kopp, and D. A. Redelmeier Prognostic Implications of Warfarin Cessation After Major Trauma: A Population-Based Cohort Analysis Circulation, May 3, 2005; 111(17): 2250 - 2256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M.W. Bath, L. Zhao, and S. Heptinstall Current status of stroke prevention in patients with atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C12 - C18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Emmerich, J.-Y. Le Heuzey, P. M.W. Bath, and S. J. Connolly Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C28 - C33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schulman and R. J. Beyth Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C34 - C40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Marti, E. Anton, D. Smadja, and S. Olindo Stroke in the Very Elderly * Response Stroke, April 1, 2005; 36(4): 705 - 706. [Full Text] [PDF]
|
|
|
|
|
|
M. W. Reynolds, K. Fahrbach, O. Hauch, G. Wygant, R. Estok, C. Cella, and L. Nalysnyk Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation: A Systematic Review and Metaanalysis Chest, December 1, 2004; 126(6): 1938 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 429S - 456S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takahashi, I. Ieiri, G. R. Wilkinson, G. Mayo, T. Kashima, S. Kimura, K. Otsubo, and H. Echizen 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients Blood, April 15, 2004; 103(8): 3055 - 3057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Snow, K. B. Weiss, M. LeFevre, R. McNamara, E. Bass, L. A. Green, K. Michl, D. K. Owens, J. Susman, D. I. Allen, et al. Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians Ann Intern Med, December 16, 2003; 139(12): 1009 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. McNamara, L. J. Tamariz, J. B. Segal, and E. B. Bass Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography Ann Intern Med, December 16, 2003; 139(12): 1018 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P.A. Jersmann, P. Girard, N. Murashige, M. Kami, Y. Takaue, M. R. Lassen, L. C. Borris, and R. L. Nakov Reviparin after Leg Injury Requiring Immobilization N. Engl. J. Med., March 13, 2003; 348(11): 1061 - 1063. [Full Text] [PDF]
|
|
|
|
|
|
H. Kato, M. Izumiyama, K. Izumiyama, A. Takahashi, and Y. Itoyama Silent Cerebral Microbleeds on T2*-Weighted MRI: Correlation with Stroke Subtype, Stroke Recurrence, and Leukoaraiosis Stroke, June 1, 2002; 33(6): 1536 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Lewis, P. A.G. Sandercock, A. Algra, the European-Australian Stroke Prevention in Rever, D. H. Hsi, D. J. Alaimo, G. Butera, M. Chessa, M. Carminati, J.P. Mohr, et al. Warfarin or Aspirin for Recurrent Ischemic Stroke N. Engl. J. Med., April 11, 2002; 346(15): 1169 - 1171. [Full Text] [PDF]
|
|
|
|
|
|
K. Nakagawa, T. Hirai, N. Shinokawa, S. Takashima, T. Nozawa, H. Asanoi, and H. Inoue Aortic Spontaneous Echocardiographic Contrast and Hemostatic Markers in Patients With Nonrheumatic Atrial Fibrillation Chest, February 1, 2002; 121(2): 500 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.P. Mohr, J.L.P. Thompson, R.M. Lazar, B. Levin, R.L. Sacco, K.L. Furie, J.P. Kistler, G.W. Albers, L.C. Pettigrew, H.P. Adams Jr., et al. A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke N. Engl. J. Med., November 15, 2001; 345(20): 1444 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Bussey Managing Excessive Warfarin Anticoagulation Ann Intern Med, September 18, 2001; 135(6): 460 - 462. [Full Text] [PDF]
|
|
|
|
|
|
N. Shinokawa, T. Hirai, S. Takashima, T. Kameyama, K. Nakagawa, H. Asanoi, and H. Inoue A Transesophageal Echocardiographic Study on Risk Factors for Stroke in Elderly Patients With Atrial Fibrillation : A Comparison With Younger Patients Chest, September 1, 2001; 120(3): 840 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Gage, S. D. Fihn, and R. H. White Warfarin Therapy for an Octogenarian Who Has Atrial Fibrillation Ann Intern Med, March 20, 2001; 134(6): 465 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart and J. L. Halperin Atrial Fibrillation and Stroke : Concepts and Controversies Stroke, March 1, 2001; 32(3): 803 - 808. [Full Text] [PDF]
|
|
|
|
 |
|
 Warfarin Treatment for Secondary Stroke Prevention in Nonvalvular AF Journal Watch Neurology, July 1, 2000; 2000(701): 3 - 3. [Full Text]
|
|